Biocept to Present at Rodman & Renshaw Global Investment Conference

SAN DIEGO--(BUSINESS WIRE)-- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer, announces that President and CEO Michael Nall is scheduled to present a corporate overview at the Rodman & Renshaw 17th Annual Global Investment Conference on September 9, 2015, at 2:10 p.m. Eastern time (11:10 a.m. Pacific time). The conference is being held at the St. Regis Hotel in New York City.

A live webcast of the presentation will be available on the investor relations page of the Company's corporate website at ir.biocept.com. A replay of the presentation will be available for 90 days.

About Biocept

Biocept, Inc. is a commercial-stage molecular diagnostics company that utilizes a proprietary technology platform and a standard blood sample to provide physicians with important prognostic and predictive information to enhance individual treatment of patients with cancer. Biocept's patented technology platform captures and analyzes circulating tumor DNA, both in CTCs and in plasma (ctDNA). Biocept currently offers assays for gastric cancer, breast cancer, lung cancer, colorectal cancer and melanoma, and plans to introduce CLIA-validated assays for prostate cancer and other solid tumors in the near term. For additional information, please visit www.biocept.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150902005064/en/

Investor Contact:
LHA, 310-691-7100
Jody Cain
jcain@lhai.com

Source: Biocept, Inc.

News Provided by Acquire Media